| Notes: |
| 1. |
The above unaudited results which are subject to limited review by the Auditors of the Company, were reviewed by the Audit Committee and have been taken on record by the Board at its meeting held on 31.1.2007. |
| 2. |
Sales for the quarter include exports of Rs.3048.9 millions (Rs.2338.0 millions). |
| 3. |
The Company's operations fall within a single primary business segment viz 'Pharmaceutical Products'. |
| 4. |
Investor complaints pending at the beginning of the quarter: Nil, received: 79, resolved: 79 and lying un-resolved at the end of the quarter: Nil. |
| 5. |
During the quarter the Company allotted 53,976 equity shares of Rs.5 each at Rs. 362.60 per share under Employees Stock Option Plan, 2004. Hence, the paid up capital stands increased to Rs.266.7 millions divided into 53.35 millions (53.27 millions) shares of Rs.5 each. |
| 6. |
Premium on redemption of USD 260 Million zero coupon Foreign Currency Convertible Bonds is contingent innature, the outcome of which is dependant on uncertain future events. |
| 7. |
With regard to addressing the qualifications of audited accounts for the year ended March 31, 2006 in the Quarterly results (a) on treatment of non-compete fee adjusted against the capital reserve, it is to explain that the issue has no impact either on the profit of March 31, 2006 or on any of the quarterly results of the current year and (b) on non-provision for diminnution in value of certain investments made in overseas subsidiaries, it is to explain that the Company has made strategic investments in manufacturing overseas subsidiaries for vertical integration.Considering nature of industry and gestation period involved, in the opinion of management, the diminution is of temporary nature and does
not require any provision. |
| 8. |
The Company has acquired during the quarter a US FDA compliant cGMP facility in Dayton, New Jersey, whichhas fully integrated state of the art R&D, formulation manufacturing and distribution facilities with potential forfuture expansion. |
| 9. |
The Company has formed during the quarter two WOS viz., APL Research Centre Limited and APL Healthcare Limited. |
| 10. |
The Company has filed with the Hon'ble High Court of Judicature of Andhra Pradesh at Hyderabad a Scheme of Arrangement (`the Scheme') for the merger of APL Life Sciences Limited and Senor Organics Pvt. Ltd., both wholly owned subsidiary Companies, with the Company and for utilisation of its Securities Premium Account. Pursuant to the direction of the Hon`ble High Court, meeting of the Equity Shareholders for approving the Scheme is scheduled to be held on February 20, 2007. Pending approval of the Hon`ble High Court, no effect of the Scheme is given in these financials. |
| 11. |
Figures for the previous periods have been rearranged/regrouped wherever necessary. |
